Safety & evidence

“Wolverine”
side effects

“Wolverine” is a seller name for a vial containing BPC-157 and TB-500. Here is what the records can and cannot tell you about safety.

Short answerSafety & evidence · 7 min read · Updated 21 Nov 2026

“Wolverine” is a seller name for a vial that mixes BPC-157 and TB-500. We found no controlled study of the two together in people (21 November 2026). FDA staff found “insufficient clinical safety information” for BPC-157, wrote that TB-500’s risks in humans “are unknown”, and say each, by the routes proposed to them, “may pose a significant risk for immunogenicity”.

Key takeaways

  • “Wolverine” is a seller name for a vial mixing BPC-157 and TB-500, not the name of a single molecule.
  • A small human case series included both substances with other agents, so it cannot establish the safety profile of the two-peptide mix.
  • FDA staff found “insufficient clinical safety information” for BPC-157, wrote that TB-500’s risks in humans “are unknown”, and say each, by the routes proposed to them, “may pose a significant risk for immunogenicity”.
  • A study plan can exclude particular groups without showing whether an exposure would harm them.

01How to read the safety record

If you searched “bpc-157 tb500 side effects”, the first answer is that an established human safety profile for the mix does not exist. Unknown does not mean that no one has reported an event. It means the available information cannot give a reliable, complete account of what may happen, how often, or to whom.

The records below answer different questions. A case series describes particular people; a spontaneous report records an event someone submitted; and a regulator’s review assesses the information available to its staff. A study registry describes a plan. None should be substituted for another.

RecordWhat it can tell you
Human case seriesWhat authors recorded for the patients described, within the limits of an uncontrolled report.
FDA safety reviewWhat agency staff identified and how they assessed the available information at the time.
Study registryWhat a sponsor planned to study and who could participate; a plan is not a finding.

For the separate question of what a tested sample contains, see how to read a COA. A lab report does not establish a human safety profile.

02What have human reports recorded?

Case series, 2026 · human observational evidence, T2. Froum and colleagues described 3 patients who received an intervention that included BPC-157 and TB-500 alongside other agents. The authors’ case-summary table listed no adverse events for the 3 patients.

That is an observation about the patients and intervention described in the paper, not a finding that the two substances are free of side effects. The report had no control group, and the patients received several agents. It cannot establish the safety of the two-peptide mix or identify the contribution of either substance. Material sold online is not the intervention described in the paper.

BPC-157 studies reviewed by FDA. FDA staff reviewed 5 small, short human studies that included BPC-157. They said serious adverse events did not appear to have been reported, but the authors supplied limited safety information and monitoring was unclear for most studies. Both parts of that assessment matter: the reported observations are not the same as a thorough safety assessment.

Those studies are not a safety study of the named mix. A small or incomplete record cannot establish whether uncommon or delayed events occur. Likewise, an observation about BPC-157 on its own should not be presented as an observation about a vial containing both substances.

03What did FDA staff report?

FAERS report. In its BPC-157 briefing, FDA described a spontaneous adverse-event report involving a product labelled as containing BPC-157 and TB-500. The report described diffuse hyperpigmentation and gingival darkening, which recurred after the person used the product again.

FDA staff considered the events likely related to the product, but said the presence of two peptides prevented an assessment of BPC-157’s role. That is an assessment of one report, not a finding about how frequently the events occur or which ingredient was responsible.

FDA also cautions that an adverse-event report does not establish that the suspect product caused the event and that the agency does not receive every report. Reports can be useful records of what was submitted, but they cannot on their own provide a side-effect rate.

FDA’s public adverse-event data. On 21 November 2026 we searched FDA’s public adverse-event data (FAERS, through openFDA, updated to 28 October 2026) for reports naming a BPC-157 product and a thymosin product together; the counts are ours. Three reports name both as suspects, and none records whether the thymosin product was TB-500. Two, from 2026, also name other suspect products: one is coded “malaise”, “blood insulin decreased”, “product dispensing error”, “product label issue”, “wrong product administered” and “manufacturing production issue”; the other “histamine abnormal” and “product quality issue”. The third, a 2021 consumer report, names “thymosin” and is coded “product sterility lacking”; its other two coded terms name a route of administration, which our pages do not print (why). All three are coded as serious. In those data, the report FDA described above lists BPC-157 as its only product. None of these reports gives a rate or shows a cause.

Other reports to FDA. FDA’s TB-500 briefing says a search of its complaint system for foods, supplements and cosmetics retrieved two cases about “blended TB-500 and BPC-157”, and that the reports did not include safety assessments. They are not confirmed reactions, and they are not evidence that a product was safe.

The agency’s two briefings used different searches and cutoffs. Their findings should be read as the results of those reviews, not as a current count of all reports. If you have a suspected reaction, seek medical care. The reaction-reporting guide explains how to report it.

04What do regulators say about the ingredients?

FDA’s compounding page says compounded drugs containing BPC-157 “may pose risk for immunogenicity for certain routes of administration” and that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans”. For TB-500, listed as thymosin beta-4 fragment (LKKTETQ), it says FDA “lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans”. Immunogenicity means the potential to prompt an immune response.

In their separate briefings, FDA staff wrote that there is “insufficient clinical safety information to characterize the safety profile” of BPC-157 and that “potential safety risks associated with the use of TB-500 in humans are unknown”; by the routes proposed to them, each “may pose a significant risk for immunogenicity”. These are ingredient-specific assessments; they do not establish a safety profile for a vial combining them.

It is important not to turn a potential risk into a claim that a particular reaction has been proven to occur. It is equally important not to turn missing information into a claim of safety. The published case series discussed above adds an observation involving several agents, but it does not resolve the gaps identified by FDA.

For more on the distinction between an ingredient and a combined product, see peptide blends. For the individual ingredient pages, see BPC-157 side effects and TB-500 side effects.

05Who was excluded from a study plan?

ClinicalTrials.gov record NCT02637284 describes a planned BPC-157 study in healthy adults, not a study of the two-peptide mix. Among its listed exclusion criteria: “Pregnant or lactating women”, “History of psychiatric condition” and “Subjects receiving medical treatment for any medical condition, either acute or chronic”. The record’s status is listed as unknown; it was last updated in December 2015.

The criteria are a plan, not an observation that someone in an excluded group experienced harm. They also cannot establish safety for that group. FDA’s briefing reported no posted results for this registry record when its staff reviewed it.

When reading any study record, distinguish the people the investigators intended to include from the people for whom results are actually available. A planned study, a completed study, and a report of study results are different kinds of information. The eligibility list is useful for understanding the limits of the plan; it is not a substitute for results.

1
Identify the population

Check who the study intended to enroll and who it excluded.

2
Check the intervention

Do not treat a single-substance study as a study of a mix.

3
Separate plans from findings

A registry entry does not by itself establish what happened to participants.

06What we don’t know

No record above gives a dependable frequency or a complete list of possible effects, and none establishes what any particular vial will do to a particular person. They also do not show that an unreported effect cannot happen.

  • Whether a particular reaction would occur with the two-peptide mix, or how often.
  • Whether observations from a multi-agent intervention apply to a vial containing two named substances.
  • What longer-term observations would show in different populations.
  • Whether a particular sample matches its label without examining the relevant testing evidence.

A lab report addresses the sample and tests it describes. It should not be mistaken for evidence that the mix has been shown safe in people.

For questions about your health, a clinician who knows you is the right person to ask. If you suspect a reaction, seek medical care first and then consider reporting it.

This is an educational summary of sources reviewed on 21 November 2026. It is not medical advice.

RefSources

  1. U.S. Food and Drug Administration. BPC-157-related bulk drug substances. Advisory committee briefing, 2026, pp. 41–42 and 46. www.fda.gov/media/193343/download
  2. U.S. Food and Drug Administration. TB-500-related bulk drug substances. Advisory committee briefing, 2026, pp. 30–31. www.fda.gov/media/193349/download
  3. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Regulator web page, accessed 21 November 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  4. Froum S, Estrin N, Pico G, et al. [Narrative review with three uncontrolled clinical cases given several agents, including BPC-157 and TB-500.] Front Oral Health, 2026;7:1907109. PMID 42876687; full text PMC13661421 read 21 Nov 2026. www.frontiersin.org/journals/oral-health/articles/10.3389/fr…
  5. ClinicalTrials.gov. NCT02637284: PCO-02 - Safety and Pharmacokinetics Trial. Registry record, last update posted 22 Dec 2015; full record read through the ClinicalTrials.gov API, 21 Nov 2026. clinicaltrials.gov/study/NCT02637284
  6. U.S. Food and Drug Administration. openFDA drug adverse event API (FAERS public data, last updated 28 Oct 2026): reports naming a BPC-157 product and a thymosin product as suspects, 19422121, 26495698, 27136848; report 26053573 looked up by number; KPV, KLOW and Wolverine as product names, no reports. Database queries, 21 Nov 2026; counts are ours. api.fda.gov/drug/event.json?search=patient.drug.medicinalpro…

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

What human safety data exist for “Wolverine”?

No study of the mix as sold. The records involving both peptides are few and uncontrolled, among them a three-patient case series and adverse-event reports, and cannot establish a safety profile for the mix.

What did the Froum case series record?

Three patients given several agents, including BPC-157 and TB-500, with no control group; its case-summary table lists “None reported” under adverse events for each. The authors write that these approaches “remain investigational, with unresolved questions concerning safety”.

Does a lab report establish human safety?

No. A report can describe specified tests on a sample; it does not establish a human safety profile.

Does exclusion from a study show that an exposure is harmful?

No. An exclusion describes who was eligible for that study. It is not a finding that an excluded person would experience harm.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page